Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Safety and Efficacy of Palliative Radiotherapy (25 Gy × 5 Fractions) for Symptomatic Pelvic Tumors

TOMOMI AOSHIKA, TAKANORI ABE, MISAKI IINO, SATOSHI SAITO, YASUHIRO RYUNO, TOMOHIRO OHTA, MITSUNOBU IGARI, RYUTA HIRAI, YU KUMAZAKI, SHIN-EI NODA and SHINGO KATO
Anticancer Research December 2022, 42 (12) 6099-6103; DOI: https://doi.org/10.21873/anticanres.16122
TOMOMI AOSHIKA
Department of Radiation Oncology, International Medical Center, Saitama Medical University, Saitama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TAKANORI ABE
Department of Radiation Oncology, International Medical Center, Saitama Medical University, Saitama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: mrtaka100{at}yahoo.co.jp
MISAKI IINO
Department of Radiation Oncology, International Medical Center, Saitama Medical University, Saitama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SATOSHI SAITO
Department of Radiation Oncology, International Medical Center, Saitama Medical University, Saitama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YASUHIRO RYUNO
Department of Radiation Oncology, International Medical Center, Saitama Medical University, Saitama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TOMOHIRO OHTA
Department of Radiation Oncology, International Medical Center, Saitama Medical University, Saitama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MITSUNOBU IGARI
Department of Radiation Oncology, International Medical Center, Saitama Medical University, Saitama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
RYUTA HIRAI
Department of Radiation Oncology, International Medical Center, Saitama Medical University, Saitama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YU KUMAZAKI
Department of Radiation Oncology, International Medical Center, Saitama Medical University, Saitama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SHIN-EI NODA
Department of Radiation Oncology, International Medical Center, Saitama Medical University, Saitama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SHINGO KATO
Department of Radiation Oncology, International Medical Center, Saitama Medical University, Saitama, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    The treatment plan of a representative patient is shown. The patient had a recurrence of ovarian cancer at the vaginal stump which caused bleeding. The light blue line shows the tumor in the figure on the left. Beams were created from 5 directions to ensure coverage of the tumor while avoiding high doses to the rectum. The dose distribution is shown in color wash, and the red thin line indicates 95% of the prescribed dose (25 Gy in 5 fractions). Diagnostic computed tomography image with contrast media of the same patient taken 6 months after treatment is shown on the right figure. The tumor shrunk well, and bleeding was controlled.

Tables

  • Figures
  • Table I.
  • Table II.
PreviousNext
Back to top

In this issue

Anticancer Research: 42 (12)
Anticancer Research
Vol. 42, Issue 12
December 2022
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Safety and Efficacy of Palliative Radiotherapy (25 Gy × 5 Fractions) for Symptomatic Pelvic Tumors
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
8 + 7 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Safety and Efficacy of Palliative Radiotherapy (25 Gy × 5 Fractions) for Symptomatic Pelvic Tumors
TOMOMI AOSHIKA, TAKANORI ABE, MISAKI IINO, SATOSHI SAITO, YASUHIRO RYUNO, TOMOHIRO OHTA, MITSUNOBU IGARI, RYUTA HIRAI, YU KUMAZAKI, SHIN-EI NODA, SHINGO KATO
Anticancer Research Dec 2022, 42 (12) 6099-6103; DOI: 10.21873/anticanres.16122

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Safety and Efficacy of Palliative Radiotherapy (25 Gy × 5 Fractions) for Symptomatic Pelvic Tumors
TOMOMI AOSHIKA, TAKANORI ABE, MISAKI IINO, SATOSHI SAITO, YASUHIRO RYUNO, TOMOHIRO OHTA, MITSUNOBU IGARI, RYUTA HIRAI, YU KUMAZAKI, SHIN-EI NODA, SHINGO KATO
Anticancer Research Dec 2022, 42 (12) 6099-6103; DOI: 10.21873/anticanres.16122
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Patients and Methods
    • Results
    • Discussion
    • Conclusion
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Palliative Radiation Treatment in Patients Managed With Advanced/Interventional Pain Therapy such as Pump-delivered Continuous Opioids
  • Google Scholar

More in this TOC Section

  • Short-term and Long-term Outcomes of Prophylactic Corticosteroid in Esophageal Cancer Surgery: A Multicenter Retrospective Study
  • Remarkable and Durable Tumor Response to Pembrolizumab in Locally Advanced dMMR/MSI-H Rectal Cancer
  • Body Weight Loss at Recurrence as an Independent Prognostic Factor in Patients With Recurrent Esophageal Cancer After Esophagectomy Who Receive First-line Treatment After Recurrence
Show more Clinical Studies

Similar Articles

Keywords

  • palliative radiotherapy
  • 25 Gy/5 fr
  • pelvic tumors
Anticancer Research

© 2025 Anticancer Research

Powered by HighWire